PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial-Reference-Cited by-同舟云学术

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

Published:2023-07 Issue: Volume:188 Page:131-139
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Loverix Liselore,Vergote Ignace,Busschaert Pieter,Vanderstichele Adriaan,Venken Tom,Boeckx Bram,Harter Philipp,Brems Hilde,Van Nieuwenhuysen Els,Pignata Sandro,Baert Thaïs,Gonzalez-Martin Antonio,Han Sileny,Marth Christian,Neven Patrick,Colombo Nicoletta,Berteloot Patrick,Mäenpää Johanna,Olbrecht Siel,Laga Tina,Sablon Erwin,Ray-Coquard Isabelle,Pujade-Lauraine Eric,Lambrechts Diether,Van Gorp Toon

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. FIGO Cancer Report 2018, targeted therapy for gynecologic cancers: toward the era of precision medicine;Basu;Int J Gynecol Obstet,2018

2. Homologous recombination deficiency and ovarian cancer;Ledermann;Eur J Cancer,2016

3. Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer;Konstantinopoulos;Cancer Discov,2015

4. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018

5. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer;Ray-Coquard;N Engl J Med,2019

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches;Frontiers in Oncology;2024-08-16

2. Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial;European Journal of Cancer;2024-07

3. Genomic alteration discordance in the paired primary-recurrent ovarian cancers: based on the comprehensive genomic profiling (CGP) analysis;Journal of Ovarian Research;2024-06-27

4. Stratification of Homologous Recombination Deficiency-Negative High-Grade Ovarian Cancer by the Type of Peritoneal Spread into Two Groups with Distinct Survival Outcomes;Cancers;2024-06-03

5. Testing dilemmas in the clinic: Lessons learned from biomarker-based drug development;Cancer Cell;2024-06